EBSEmergent BioSolutions Inc.
Is it safe?
Caution warranted: heavy debt (CCC) and big price swings.
Insiders were net sellers (-$126K, 90 days to Oct 22, 2026), selling is often routine.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -99% · now 55% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can EBS take a bad year?
Emergent BioSolutions Inc. carries $442M of net debt as at Q2 2026, with no operating profit to service it.
Net debt · as at Q2 2026 · debt less the cash on hand, with no positive EBITDA to service it
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
- Annualised volatility
- 86%
Annualised volatility · S&P 500 16% · about 5 times the market's own swing
- Worst drawdown on file
- −99%
Worst drawdown on file · −55% today
Details›
- Total debtQ2 2026
- $582M
- Cash and short-term investments
- $140M
- Net debt
- $442M
- EBITDA, trailing twelve months
- −$5.1M
- Operating profit, trailing twelve months
- −$66M
- Debt / equity
- 1.70×
- Annualised volatilitytwo years of daily moves
- 86%
- Worst drawdown on file
- −99%
- Below its 52-week high
- 55%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
The balance sheet
What it owes against what it owns, and how close that comes to trouble.
How far can it fall?
How much the price moves, how deep and how long its falls have run, and what each unit of risk has paid.
Drug Manufacturers, Specialty & Generic
Ranks #28 of 39 by RyuScore